Cerexa is a biopharmaceutical company produces a portfolio of anti-infective therapies for the treatment of life-threatening infections.
Cerexa is a biopharmaceutical company focused on the development of a portfolio of novel anti-infective therapies for the treatment of serious and life-threatening infections. The company’s product portfolio includes Ceftaroline AcetateCeftaroline, an injectable cephalosporin that is used for the treatment of bacterial infections caused by gram-positive and gram-negative pathogens.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 23, 2005 | Series A | $50M | 1 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
EGS Healthcare Capital Partners
|
— | Series A |